The companies are looking to get Relistor approved for the treatment of opioid-induced constipation (:OIC) in patients taking opioids for chronic non-cancer pain. Relistor is a peripherally acting ...
Marketing Approval Expands Treatment to Include Nearly 11 Million Patients Who Experience Opioid-Induced Constipation While Taking Opioids for Chronic Non-Cancer Pain RALEIGH, N.C. & TARRYTOWN, N.Y.-- ...
Data from a Post-Hoc Analysis Supports the Use of Salix's RELISTOR for Patients with Opioid-Induced Constipation and Advanced Illness in the Emergency Department Setting LAVAL, QC, Dec. 22, 2021 ...
With oral Relistor's approval, Valeant just got a new weapon in its battle with AstraZeneca for the opioid-induced constipation throne. Can that weapon reach the billion-dollar sales benchmark quoted ...
Salix Pharmaceuticals (NASDAQ:SLXP) must wait a little longer for a regulatory decision on its constipation treatment Relistor. An approval decision was expected on April 27. But the U.S. Food and ...
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that the Committee for Medicinal Products for Human Use (CHMP) of ...
Relistor is a drug that people use to treat constipation that opioid medications can cause. Relistor is effective because it does so without reducing the pain-relieving effects of the opioid drugs.
LAVAL, Quebec and TARRYTOWN, N.Y., April 24, 2015 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Salix Pharmaceuticals (NASDAQ:SLXP) is a step closer to bringing to the U.S. Food and Drug Administration a once-a-day pill version of injectable constipation drug Relistor. Discover the top ...
Wyeth Pharmaceuticals, a division of Wyeth, and Progenics Pharmaceuticals, Inc., announced that the companies have received marketing approval for RELISTOR (methylnaltrexone bromide) subcutaneous ...
NEW YORK, Oct 14 (Reuters) - Progenics Pharmaceuticals Inc said on Wednesday it reached a deal with Wyeth to regain worldwide rights to Relistor, a medicine used to treat constipation caused by opioid ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results